Kestra Medical Technologies, Ltd.
NASDAQ:KMTSMedical - Instruments & Supplies
-$0.07 today
- Market cap
- $1.69B
- Beta
- 0.83
- P/E (TTM)
- -6.9
- EPS (TTM)
- -$2.74
Volume 0.44M
Average 0.33M
KMTS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Kestra Medical Technologies, Ltd.NASDAQ: KMTS
Cash & Equivalents · Q3 FY2026 · quarter ended Jan 2026
Cash & equivalents rises 436.0% from a year ago
Cash & equivalents stood at $291.32M at the end of Q3 FY2026, up 436.0% from a year earlier and up 66.1% from the prior quarter.
Context
- Cash & equivalents amounted to 76.8% of total assets at the end of Q3 FY2026, up 26.5 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +436.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 237.6M USD
- Year-over-year change
- +2780.3%
- 5-year CAGR
- +110.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | 237.6M | +2780.3% |
| FY2024 | 2024-04-30 | 8.25M | -44.3% |
| FY2023 | 2023-04-30 | 14.81M | — |
| FY2021 | 2021-04-30 | 24.34M | +322.9% |
| FY2020 | 2020-04-30 | 5.76M | — |
Cash & Equivalents vs competitors
How KMTS compares with its peers on the latest reported figures
- KMTS's Jan 2026 cash & equivalents of $291.32M is the 2nd highest of the 3 companies compared; the peer median is $233.51M.
- Its year-over-year change of +436.0% is the highest of 3, against a peer median of +12.4%.
- Cash & equivalents amounts to 76.8% of total assets for KMTS, versus a peer median of 54.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $394.72M | +54.4% | +44.1% | 36.2% | |
| Jan 2026 | $291.32M | +436.0% | — | 76.8% | |
| Mar 2026 | $72.3M | -29.6% | -10.7% | 72.5% | |
| Peer median (excluding KMTS) | $233.51M | +12.4% | +16.7% | 54.3% | |
Competitors are the stored peer set for KMTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2020 Apr 2020 | FY2021 Apr 2021 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5.76M | 24.34M | 14.81M | 8.25M | 237.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 2.11M | 2M | 8.08M |
| Inventory | 0 | 0 | 2.11M | 3.29M | 6.57M |
| Other Current Assets | 209K | 1.35M | (1.74M) | 419K | 1.69M |
| Total Current Assets | 6.17M | 26.2M | 18.42M | 14.91M | 255.33M |
| Property, Plant & Equipment (Net) | 1.13M | 3.08M | 16.72M | 28.39M | 36.91M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 580K | 1.24M | 3.51M | 2.65M | 3.51M |
| Total Non-current Assets | 1.71M | 4.33M | 20.23M | 31.04M | 40.42M |
| Total Assets | 7.87M | 30.52M | 38.66M | 45.95M | 295.74M |
| Account Payables | 1.83M | 1.7M | 6.16M | 23.89M | 23.96M |
| Short-term Debt | 0 | 0 | 20.45M | 0 | 187K |
| Tax Payables | 68K | 42K | 215K | 234K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 4.67M | 6.19M | 8.49M |
| Total Current Liabilities | 4.02M | 6.61M | 36.74M | 32.97M | 37.98M |
| Long-term Debt | 0 | 20.24M | 17.32M | 42.54M | 41.1M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 360K | 102.17M | 177.19M | 8.24M |
| Total Non-current Liabilities | 0 | 22.15M | 119.5M | 222.36M | 52.36M |
| Total Liabilities | 4.02M | 28.76M | 156.23M | 255.33M | 90.34M |
| Common Stock | 1K | 1K | 1K | 1K | 51.35M |
| Retained Earnings | (135.98M) | (170.08M) | (312.32M) | (406.44M) | (520.25M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 3.86M | 1.77M | (117.58M) | (209.38M) | 205.41M |
| Total Debt | 452K | 22.85M | 39.13M | 45.17M | 44.31M |
| Net Debt | (5.3M) | (1.49M) | 24.32M | 36.92M | (193.28M) |
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
Intrinsic Alpha fair value
Locked
Current Price
$28.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.